DOCSLIB.ORG

INTEGRIS Formulary July 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

INTEGRIS Formulary July 2017 Foreword FORMULARY EXCLUDED THERAPEUTIC DRUG This document represents the efforts of the MedImpact Healthcare Systems THERAPEUTIC DRUGS CLASS Pharmacy and Therapeutics (P & T) and Formulary Committees to provide ALTERNATIVES physicians and pharmacists with a method to evaluate the safety, efficacy and cost- clindamycin/tretinoin, ACNE AGENTS, effectiveness of commercially available drug products. A structured approach to the VELTIN drug selection process is essential in ensuring continuing patient access to rational ZIANA TOPICAL drug therapies. The ultimate goal of the MedPerform Formulary is to provide a morphine sulfate ER process and framework to support the dynamic evolution of this document to guide tablets, oxycodone ANALGESICS, KADIAN prescribing decisions that reflect the most current clinical consensus associated ER, NUCYNTA, NARCOTICS with drug therapy decisions. NUCYNTA ER ANALGESICS, This is accomplished through the auspices of the MedImpact P & T and Formulary BELBUCA BUTRANS PATCH Committees. These committees meet quarterly and more often as warranted to NARCOTICS ensure clinical relevancy of the Formulary. To accommodate changes to this ABSTRAL, document, updates are made accessible as necessary. FENTORA, fentanyl citrate ANALGESICS, LAZANDA, lozenge NARCOTICS As you use this Formulary, you are encouraged to review the information and ONSOLIS, provide your input and comments to the MedImpact P & T and Formulary SUBSYS Committees. immediate-release GRALISE ANTICONVULSANTS The MedImpact P & T and Formulary Committees use the following criteria in the gabapentin evaluation of drug selection for the MedPerform Formulary: • Drug safety profile ACTIVE-PAC immediate-release • Drug efficacy gabapentin & KIT, • Comparison of relevant therapeutic benefits to current formulary agents of lidocaine/menthol SMARTRX similar use, and to minimize therapeutic duplication where possible topical, or ANTICONVULSANTS • GABA-V KIT, Cost-effectiveness relative to comparable therapies capsaicin/methyl SMART RX salicylate/menthol How to Use the Formulary GABA KIT The Formulary is a list of medications available to MedImpact members under their topical pharmacy benefit. All drugs are listed by their generic names and most common proprietary (branded) name. The Formulary may be accessed by using the index, immediate-release ANTICONVULSANTS either by generic or proprietary name (in capital letters) and by therapeutic drug gabapentin, (RESTLESS LEG HORIZANT category. In situations where an FDA approved generic equivalent is available, ropinirole, SYNDROME/POST brand names are listed for reference purposes only, and do not denote coverage pramipexole HERPETIC NEURALGIA) for the brand, unless specifically noted. Any drug not found in this Formulary listing, or any Formulary updates published by MedImpact shall be considered a FORFIVO XL bupropion ER ANTIDEPRESSANTS Non-Formulary drug. IRENKA duloxetine ANTIDEPRESSANTS desvenlafaxine All drugs are listed in each category in alphabetical order by generic name. Where succinate ER, KHEDEZLA ANTIDEPRESSANTS an FDA approved generic is available for the listed generic name, the generic name desvenlafaxine ER is bolded. (Ranbaxy) For certain agents within the Formulary, a recommended prescribing guideline may PEXEVA paroxetine ANTIDEPRESSANTS apply. These are denoted throughout the document using the following symbols: ZUPLENZ ondansetron ODT ANTIEMETIC AGENTS AGE Age Edit Coverage may depend on patient age NYATA nystatin topical ANTI-INFECTIVE CU Concurrent Coverage or lack thereof may depend upon Use Edit concurrent use of another drug DAXBIA cephalexin ANTI-INFECTIVE MD Physician Coverage may depend on prescribing physician’s ZIPSOR, ANTI-INFLAMMATORY Specialty Edit specialty or board certification diclofenac ZORVOLEX NON-STEROIDAL PA Prior Requires specific physician request process ANTI-INFLAMMATORY NAPRELAN naproxen Authorization NON-STEROIDAL ANTI-INFLAMMATORY VIVLODEX meloxicam QL Quantity Coverage may be limited to specific quantities NON-STEROIDAL Limit per prescription and/or time period ANTI-INFLAMMATORY ST Step Therapy Coverage may depend on previous use of another TIVORBEX indomethacin drug NON-STEROIDAL naproxen & Please refer to the prescribing guideline appendix within this document for details esomeprazole ANTI-INFLAMMATORY regarding specific agents. magnesium, VIMOVO NON-STEROIDAL lansoprazole, COMBINATION AGENTS Benefit Coverage and Limitations omeprazole, or This printed Formulary does not provide information regarding the specific coverage and limitations an individual member may be subject to. Many members pantoprazole ANTI-INFLAMMATORY have specific benefit inclusions, exclusions, copays, or a lack of coverage, which famotidine & are not reflected in the Formulary. DUEXIS NON-STEROIDAL ibuprofen COMBINATION AGENTS The Formulary applies only to outpatient drugs provided to members, and does not APTENSIO dextroamphetamine/ ATTENTION DEFICIT- apply to medications used in inpatient settings. If a member has any specific XR, questions regarding their coverage, they should contact their Plan Sponsor or amphetamine, HYPERACTIVITY ADZENYS XR MedImpact at (800) 788-2949. methylphenidate (ADHD)/NARCOLEPSY ODT Excluded Agents immediate-release ANTI-INFLAMMATORY RAYOS As new drugs become available, they will be considered for coverage under the prednisone STEROIDAL MedPerform Formulary. The plan administrator has the right to decide what drugs ZONACORT, dexamethasone ANTI-INFLAMMATORY are covered and to what extent, as well as the right to modify coverage including LOCORT 1.5mg tab STEROIDAL the exclusion of any prescription drugs. Please note that prescribing guidelines diphenoxylate/atropi such as Prior Authorization, Step Therapy, Quantity Limit, etc., may still apply to MOTOFEN ANTI-MOTILITY Formulary Therapeutic Alternatives. ne INTEGRIS Formulary – July 2017 iii INTEGRIS Formulary FORMULARY FORMULARY EXCLUDED THERAPEUTIC DRUG EXCLUDED THERAPEUTIC DRUG THERAPEUTIC THERAPEUTIC DRUGS CLASS DRUGS CLASS ALTERNATIVES ALTERNATIVES codeine/pseudoephe LEVITRA, HYCOFENIX ANTITUSSIVES DRUGS TO TREAT drine/guaifenesin sol STENDRA, VIAGRA IMPOTENCY ANTI-INFLAMMATORY STAXYN celecoxib & NON-STEROIDAL EMERGENCY epinephrine 0.3mg CAPXIB capsaicin/menthol CYCLOOXYGENASE-2 TREATMENT OF AUVI-Q or 0.15mg auto- topical patch (COX-2) SELECTIVE ALLERGIC REACTIONS injector INHIBITOR (TYPE 1) HUMIRA, ENBREL, VIEKIRA PAK, HARVONI, HEPATITIS C COSENTYX, DAKLINZA EPCLUSA STELARA, CIMZIA, HORMONAL XELJANZ/XR,OTEZ ESTROGEL DIVIGEL KEVZARA, DEFICIENCY LA, *SIMPONI AUTOIMMUNE DISEASE SIMPONI NATESTO, 100mg (*for 50mg, TALTZ TESTIM, ANDROGEL, HORMONAL diagnosis of VOGELXO, AXIRON DEFICIENCY ulcerative colitis FORTESTA only) GENOTROPI alendronate 70mg, BONE RESORPTION N, BINOSTO ibandronate INHIBITORS HUMATROPE aspirin (OTC), , NUTROPIN, DURLAZA CARDIOLOGY NUTROPIN OMNITROPE, clopidogrel GROWTH HORMONES AQ, NORDITROPIN YOSPRALA aspirin (OTC) CARDIOLOGY NUTROPIN GONITRO nitroglycerin CARDIOLOGY AQ NUSPIN, KELOCOTE, BEAU RX DERMATOLOGY SAIZEN, RECEDO ZOMACTON DERMAPAK amlodipine and tretinoin topical DERMATOLOGY PRESTALIA HYPERTENSION PLUS benazepril hcl APIDRA, ACCUCAINE lidocaine topical DERMATOLOGY APIDRA SOLOSTAR, PEDIPAK ciclopirox DERMATOLOGY HUMALOG INSULINS NOVOLOG, OTC EMOLLIENTS NOVOLOG (EUCERIN, FLEXPLEN SYNERDERM CETAPHIL, DERMATOLOGY LEVEMIR, VASELINE, BASAGLAR, LANTUS, TOUJEO INSULINS AQUAPHOR) TRESIBA URE-K, NOVOLIN HUMULIN INSULINS KERALAC, atorvastatin, UTOPIC, lovastatin, urea 40%, urea 50% DERMATOLOGY ALTOPREV, UREVAZ, pravastatin, LIPID IRREGULARITY LESCOL XL DERMASORB simvastatin, XM rosuvastatin diclofenac sodium DERMATOLOGY - PENNSAID fenofibrate/ 1% topical ANTIINFLAMMATORY ANTARA micronized/ LIPOTROPICS ADLYXIN, nanocrystallized BYDUREON, TRULICITY, balsalazide DIABETES LOWER BYETTA, VICTOZA DELZICOL, disodium, APRISO, GASTROINTESTINAL TANZEUM DIPENTUM LIALDA, PENTASA, TRULICITY, DISORDERS XULTOPHY, sulfasalazine VICTOZA, LANTUS, DIABETES SOLIQUA ONZETRA, TOUJEO ZEMBRACE sumatriptan MIGRAINE INVOKANA, SYMTOUCH, INVOKAMET, TREXIMET FARXIGA, INVOKAMET XR, DIABETES REBIF, GILENYA, XIGDUO XR JARDIANCE, PLEGRIDY, SYNJARDY, TECFIDERA, EXTAVIA MULTIPLE SCLEROSIS SYNJARDY XR AVONEX, GLUMETZA metformin ER DIABETES GLATOPA, NESINA, JENTADUETO, AUBAGIO KAZANO, JENTADUETO XR, Individual vitamin MULTIVITAMIN METHAVER OSENI, TRADJENTA, components PREPARATIONS DIABETES ONGLYZA, JANUVIA, Nasal triamcinolone, OMNARIS, KOMBIGLYZE JANUMET, flunisolide, ZETONNA, XR JANUMET XR fluticasone, NASAL ANTI- BECONASE ALL OTHER budesonide, INFLAMMATORY MANUFACTU AQ, ABBOTT mometasone, RERS OF DIABETIC SUPPLIES TICANASE (PRECISION AND QNASL DIABETIC (TEST STRIPS, NASAL ANTI- FREESTYLE azelastine & TEST STRIPS METERS) INFLAMMATORY/ANTI- BRAND) TICALAST fluticasone nasal AND HISTAMINE sprays METERS COMBINATION phentermine & QSYMIA OBESITY AGENTS topiramate 37012 MedPerform Medium Formulary – July 2017 iv INTEGRIS Formulary FORMULARY • EXCLUDED THERAPEUTIC DRUG A multi-source drug product manufactured by at least one (1) nationally THERAPEUTIC DRUGS CLASS marketed company. ALTERNATIVES • At least one (1) of the generic manufacturer’s products must have an latanoprost, “A” rating or the generic product has been determined to be travoprost, OPHTHALMIC unassociated with efficacy, safety or bioequivalency concerns by the ZIOPTAN LUMIGAN, GLAUCOMA MedImpact P & T Committee. TRAVATAN Z • Drug product will be approved for generic substitution by the NARCAN NASAL MedImpact P & T Committee. EVZIO
Recommended publications
  • Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study

    Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study

    Klinik für Infektiologie & Spitalhygiene Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study Andreas Neumayr, Mirjam Schunk, Caroline Theunissen, Marjan Van Esbroeck, Matthieu Mechain, Manuel Jesús Soriano Pérez, Kristine Mørch, Peter Sothmann, Esther Künzli, Camilla Rothe, Emmanuel Bottieau Journal Club 01.03.21 Andreas Neumayr Background on giardia treatment: • 1st-line treatment: 5-nitroimidazoles: metronidazole (1957), tinidazole, ornidazole, secnidazole • cure rate of 5NIs in 1st-line treatment: ~90% • in the last decade, an increase of 5NI-refractory giardia cases has been observed in travel medicine clinics across Europe: Hospital for Tropical Diseases, London: 2008: 15% --> 2013: 40% 70% of 5NI-refractory cases imported from India • 2nd-line treatment: effectiveness of a 2nd round with a 5NI: ~17% alternative drugs: albendazole, mebendazole, nitazoxanide, quinacrine, furazolidone, chloroquine, paromomycin 2012 TropNet member survey: 53 centres use 39 different treatment regimens, consisting of 7 different drugs in mono- or combination-therapy in various dosages and durations JC 01.03.21 Nabarro LE et al. Clin Microbiol Infect. 2015;21:791-6. • by 2013, there were only 13 reports of 2nd-line therapy for giardiasis (8 case series, 5 individual case reports): n=110 Cure rates Albendazole 6/32 18.7% Paromomycin 5/17 29.4% Nitazoxanide 2/5 40.0% Albendazole + 5-NI 42/53 79.2% Quinacrine 19/21 90.5% Quinacrine + 5-NI 14/14 100% Quinacrine + Paromomycin 2/2 100% • 2013: TropNet "GiardiaREF" study kick-off: Study on efficacy and tolerability of two 2nd-line regimens in nitroimidazole-refractory giardiasis: Quinacrine JC 01.03.21 Meltzer E et al.
  • Fluoxymesterone-Dea Schedule Iii Androfluorene

    Fluoxymesterone-Dea Schedule Iii Androfluorene

    Cat. No. F7751 FLUOXYMESTERONE--DEA SCHEDULE III ANDROFLUORENE Androgen. OH Mol. Formula: C20H29FO3 HO H3C CH3 Mol. Wt.: 336.45 (anhyd.) F H3C m.p.: 288-290°C CAS Registry No.: 76-43-7 O Chemical Name: 4-Androsten-9a-fluoro-17a-methyl-11b,17b-diol-3-one 22 Physical Properties: White photosensitive solid. [a] D = +102.34° (c = 0.47, EtOH). Caution: Due care should be exercised to prevent skin contact, ingestion or inhalation of this compound. Storage: Store tightly sealed at room temperature, protected from exposure to light. Solubility: Soluble in ethanol (7.3 mg/ml) or water (< 0.5 mg/ml). Solubility in 45% aqueous (w/v) 2-hydroxypropyl-b- cyclodextrin (Cat. No. H-107): 6.4 mg/ml. Disposal: Dissolve or mix the compound with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. This product is controlled by the Drug Enforcement Administration. Appropriate security must be maintained until the substance is destroyed. Records must be kept which detail the ultimate disposition of the material. References: 1. Merck Index 11th Ed., No. 4113. 2. Saborido, A., Vila, J., Molano, F., Megias, A. “Effect of steroids on mitochondria and sarcotubular system of skeletal muscle.” J. Appl. Physiol. 70(3), 1038 (1991). 3. Fernandez, L., Chirino, R., Boada, L.D., Navarro, D., Cabrera, N., del Rio, I., Diaz-Chico, B.N. “Stanozolol and danazol, unlike natural androgens, interact with the low affinity glucocorticoid-binding sites from male rat liver microsomes.” Endocrinology 134(3), 1401 (1994). CONTROLLED SUBSTANCE - DEA LICENSE REQUIRED (III) Rev.
  • Jos Journal 2

    Jos Journal 2

    POST-OPERATIVE AUDIT OF G6PD-DEFICIENT MALE CHILDREN WITH OBSTRUCTIVE ADENOTONSILLAR ENLARGEMENT AT UNIVERSITY COLLEGE HOSPITAL, IBADAN, NIGERIA. John EN1, Totyen EL1, Jacob N2, Nwaorgu OGB1 1 .Department of ENT/Head and Neck Surgery, University College Hospital, Ibadan, Nigeria 2. Department of paediatrics, University College Hospital, Ibadan, Nigeria All correspondences and request for reprint to Dr John EN, Department of ENT/Head and Neck Surgery, University College Hospital, Ibadan, Nigeria Email: [email protected] Telephone: +2348036240109 Abstract Background: G6PD deficiency ranks among the commonest hereditary enzyme deficiency worldwide and notable as a predisposing condition to haemolyticcrises. The fear of possible untoward effects is often expressed by parents of G6PD deficient male children scheduled for surgery after obtaining an informed and understood consent. The parental perception of obstructive adenotonsillar enlargement in this condition was also appraised. Methods: A retrospective chart review of all G6PD deficient male children between ages 1 to 7years who had adenotonsillectomy over a 3year period at University college Hospital, Ibadan, Nigeria. Results: The patients comprised of 22 G6PD deficient male children diagnosed shortly after birth upon development of neonatal jaundice. Fifteen(68.2%) and 6(27.3%) of the patients subsequently developed episodes of drug- induced haemolysis and non-haemolytic drug reactions prior to undergoing adenotonsillectomy by the otolaryngologists. None of the patients was observed to develop haemolytic crises up to 2weeks post-adenotonsillectomy. From the parental perception and responses in the follow-up period,all 22(100%) patient had resolution of noisy breathing, 20(91%) had improvement of snoring and apnoeic spells. Only 15 (68%) were reported to stop mouth-breathing.
  • 30 Day Change Notice Effective Date

    30 Day Change Notice Effective Date

    30 Day Change Notice Effective Date: January 1st, 2021 NEW PREFERRED DRUGS THERAPEUTIC CLASS NO PA REQUIRED PREFERRED Central Nervous System (CNS) Agents: Anticonvulsants Clobazam (Generic of Onfi) Central Nervous System (CNS) Agents: Multiple Aubagio EndocrineSclerosis Agents: Osteoporosis-Bone Ossification Forteo Enhancers Gastrointestinal Agents: Anti-Emetics Bonjesta Genitourinary Agents: Benign Prostatic Hyperplasia Alfuzosin (Generic of Uroxatral) Dutasteride (Generic of Avodart) Genitourinary Agents: Electrolyte Depleter Agents Sevelamer (Generic of Renagel and Renvela) Infectious Disease Agents: Antibiotics-Macrolides Eryped Infectious Disease Agents: Antivirals-HIV Atazanavir Sulfate Oral Powder (Generic of Reyataz) Tivicay PD Infectious Disease Agents: Antibiotics-Tetracyclines Vibramycin Suspension (no PA Required for age 12 or under) Ophthalmic Agents: Antibiotics and Antibiotic -Steroid Neomycin/Polymyxin/Bacitracin/Hydrocortisone Ointment Combination Drops and Ointments Ophthalmic Agents: Glaucoma Agents Dorzolamide/Timolol (Generic of Cosopt PF) NEW CLINICAL PA REQUIRED “PREFERRED” DRUGS THERAPEUTIC CLASS CLINICAL PA REQUIRED PREFERRED Blood Formation, Coagulation, and Thrombosis Agents: Corifact Hemophilia Factors Immunomodulator Agents for Systemic Inflammatory Taltz Disease Immunomodulator Agents for Systemic Inflammatory Xeljanz 5mg Disease NEW STEP THERAPY REQUIRED “PREFERRED” THERAPEUTIC CLASS STEP THERAPY REQUIRED “PREFERRED” Central nervous System (CNS) Agents: Anti-Migraine, Aimovig Prophylaxis Treatment Ajovy
  • Active Pharmaceutical Ingredients

    Active Pharmaceutical Ingredients

    Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom

    Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom

    No. LCMSMS-065E Liquid Chromatography Mass Spectrometry Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole No. LCMSMS-65E Mass Spectrometry This application news presents a method for the determination of 17 hormone residues in milk using Shimadzu Ultra-High-Performance Liquid Chromatograph (UHPLC) LC-30A and Triple Quadrupole Mass Spectrometer LCMS- 8040. After sample pretreatment, the compounds in the milk matrix were separated using UPLC LC-30A and analyzed via Triple Quadrupole Mass Spectrometer LCMS-8040. All 17 hormones displayed good linearity within their respective concentration range, with correlation coefficient in the range of 0.9974 and 0.9999. The RSD% of retention time and peak area of 17 hormones at the low-, mid- and high- concentrations were in the range of 0.0102-0.161% and 0.563-6.55% respectively, indicating good instrument precision. Method validation was conducted and the matrix spike recovery of milk ranged between 61.00-110.9%. The limit of quantitation was 0.14-0.975 g/kg, and it meets the requirement for detection of hormones in milk. Keywords: Hormones; Milk; Solid phase extraction; Ultra performance liquid chromatograph; Triple quadrupole mass spectrometry ■ Introduction Since 2008’s melamine-tainted milk scandal, the With reference to China’s national standard GB/T adulteration of milk powder has become a major 21981-2008 "Hormone Multi-Residue Detection food safety concern. In recent years, another case of Method for Animal-derived Food - LC-MS Method", dairy product safety is suspected to cause "infant a method utilizing solid phase extraction, ultra- sexual precocity" (also known as precocious puberty) performance liquid chromatography and triple and has become another major issue challenging the quadrupole mass spectrometry was developed for dairy industry in China.
  • Annex 4: Drug Dosages for Children (Formulary)

    Annex 4: Drug Dosages for Children (Formulary)

    Medicines Dosage Form Dose according to body weight (calculate if weight is below or over) 3-6 kg 6-10 kg 10-15 kg 15-20 kg 20-29 kg albendazole 200 mg (half tablet) 12-24 months chewable tablet, 400mg 400 mg (one tablet) over 24 months amodiaquine 10 mg base/kg/3 days (total dose 30 mg base/kg) tablet, 200mg - - 1 1 1 amoxicillin 15 mg/kg/dose for 7 days tablet/capsule 250 mg ¼ ½ ¾ 1 1½ oral suspension, 125mg/5ml 2.5 ml 5 ml 7.5 ml 10 ml - non-severe pneumonia: 25 mg/kg 2 times per day for 3 days tablet/capsule 250 mg ½ 1 1½ 2 2½ oral suspension, 125mg/5ml 5 ml 10 ml 15 ml - - ampicillin IM 50 mg/kg/6 hours Vial of 500 mg mixed with 2.1 ml 1 ml 2 ml 3 ml 5 ml 6 ml sterile water to give 500 mg/2.5 ml artemether IM 3.2 mg/kg once on day 1 injection, 40mg/ml in 1ml ampoule then injection, 80mg/ml in 1ml ampoule see Chapter 5, management of the child with malaria IM 1.6 mg/kg daily until oral therapy is possible, total therapy one week artemether + fixed dose treatment (20+120 mg) twice daily for 3 days tablet 10+120 mg see Chapter 5, management of the child with malaria lumefantrine artesunate severe malaria: IV or IM 2.4 mg/kg over 3 minutes at 0, 12 and 24 vial of 60 mg in 0.6 ml with 3.4 ml hours on day 1.
  • Medperform Low Formulary July 2017

    Medperform Low Formulary July 2017

    MedPerform Low Formulary July 2017 Foreword FORMULARY This document represents the efforts of the MedImpact Healthcare Systems EXCLUDED THERAPEUTIC THERAPEUTIC DRUG CLASS Pharmacy and Therapeutics (P & T) and Formulary Committees to provide DRUGS physicians and pharmacists with a method to evaluate the safety, efficacy and cost- ALTERNATIVES effectiveness of commercially available drug products. A structured approach to the clindamycin/tretinoin, VELTIN ACNE AGENTS, TOPICAL drug selection process is essential in ensuring continuing patient access to rational ZIANA drug therapies. The ultimate goal of the MedPerform Formulary is to provide a morphine sulfate ER process and framework to support the dynamic evolution of this document to guide tablets, oxycodone ER, ANALGESICS, prescribing decisions that reflect the most current clinical consensus associated KADIAN with drug therapy decisions. NUCYNTA, NUCYNTA NARCOTICS ER This is accomplished through the auspices of the MedImpact P & T and Formulary ANALGESICS, BELBUCA BUTRANS PATCH Committees. These committees meet quarterly and more often as warranted to NARCOTICS ensure clinical relevancy of the Formulary. To accommodate changes to this ABSTRAL, document, updates are made accessible as necessary. FENTORA, ANALGESICS, LAZANDA, fentanyl citrate lozenge As you use this Formulary, you are encouraged to review the information and NARCOTICS provide your input and comments to the MedImpact P & T and Formulary ONSOLIS, Committees. SUBSYS immediate-release GRALISE ANTICONVULSANTS The MedImpact
  • Anabolic Steroids/Androgens Pa Summary

    Anabolic Steroids/Androgens Pa Summary

    ANABOLIC STEROIDS/ANDROGENS PA SUMMARY PREFERRED Anadrol-50, Danazol, Fluoxymesterone, Methitest, Oxandrolone, Testosterone Cypionate Injection, Testosterone Enanthate Injection NON-PREFERRED Android, Testred LENGTH OF AUTHORIZATION: Varies NOTE: All preferred and non-preferred agents require prior authorization. See PA criteria labeled “Topical Testosterone” for Androderm, Androgel, Striant, and Testim. The criteria details below are for the outpatient pharmacy program. If an injectable medication is being administered in a physician’s office then the criteria information below does not apply. Instead, the physician’s office must bill this drug through the DCH physician’s injectable program and not the outpatient pharmacy program. Information regarding the physician’s injectable program can be located at www.mmis.georgia.gov. PA CRITERIA: For Anadrol-50 Approvable for the following diagnoses: anemia caused by deficient red blood cell production, acquired or congenital aplastic anemia, myelofibrosis, hypoplastic anemia due to administration of myelotoxic drugs Also approvable for HIV or AIDS wasting when significant weight loss is documented in members currently receiving nutritional support For Danazol Approvable for the following diagnoses: endometriosis, fibrocystic breast disease, hereditary angioedema For Fluoxymesterone, Methyltestosterone (Android, Methitest, Testred), Testosterone Cypionate or Enanthate Injection Approvable in male members 12 years of age or older for the following diagnoses: primary hypogonadism, secondary
  • Printed Formulary Catalog Basic

    Printed Formulary Catalog Basic

    Scripps Health Formulary July 2016 Foreword Pharmacy and Therapeutics Committee. MedImpact approves such multi- This document represents the efforts of the MedImpact Healthcare Systems source drugs for addition to the MAC list based on the following criteria: Pharmacy and Therapeutics (P & T) and Formulary Committees to provide physicians A multi-source drug product manufactured by at least one (1) nationally and pharmacists with a method to evaluate the safety, efficacy and cost-effectiveness marketed company. of commercially available drug products. A structured approach to the drug selection At least one (1) of the generic manufacturer’s products must have an “A” process is essential in ensuring continuing patient access to rational drug therapies. rating or the generic product has been determined to be unassociated with The ultimate goal of the Portfolio Formulary is to provide a process and framework to efficacy, safety or bioequivalency concerns by the MedImpact P & T support the dynamic evolution of this document to guide prescribing decisions that Committee. reflect the most current clinical consensus associated with drug therapy decisions. Drug product will be approved for generic substitution by the MedImpact P & T Committee. This is accomplished through the auspices of the MedImpact P & T and Formulary Committees. These committees meet quarterly and more often as warranted to ensure This list is reviewed and updated periodically based on the clinical literature and clinical relevancy of the Formulary. To accommodate changes to this document, pharmacokinetic characteristics of currently available versions of these drug updates are made accessible as necessary. products. As you use this Formulary, you are encouraged to review the information and provide If a member or physician requests a brand name product in lieu of an approved your input and comments to the MedImpact P & T and Formulary Committees.
  • Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole

    Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole

    Research Article Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole Luciana F. Macedo, Zhiyong Guo, Syreeta L. Tilghman, Gauri J. Sabnis, Yun Qiu, and Angela Brodie Department of Pharmacology and Experimental Therapeutics, University of Maryland, Baltimore, Maryland Abstract hormone therapy and longer patient survival (14). However, the Previous work has shown that androgens inhibit breast cancer physiologic role of endogenous androgens and events following AR cells and tumor growth. On the other hand, androgens can be activation leading to inhibition of cell growth are not clearly identified in breast cancer cells. Some studies have shown that converted to mitogenic estrogens by aromatase in breast cancer cells. Here, we report that androgens, such as the androgens modulate the expression of the Bcl-2protein family in aromatizable androstenedione and the non-aromatizable breast cancer cells, and that their effect is contrary to that of 5A-dihydrotestosterone, inhibit MCF-7 cell proliferation. This estrogens (15, 16). The Bcl-2family proteins both inhibit and effect is observed only in the absence or at a low concentra- promote cell death (16, 17), and the Bcl-2protein has been tion of estrogens and is evident in cells with low aromatase extensively characterized as an inhibitor of apoptosis. activity. Growth of a new aromatase stably transfected MCF-7 Due to their adverse side effects, exogenous androgens were later cell line (Ac1) was stimulated by conversion of androstene- replaced by other better tolerated breast cancer treatment dione into estrogens and was sensitive to aromatase inhib- strategies, such as ER antagonism and aromatase inhibition.